UnitedHealth Group, one of the largest health-care companies in the U.S., is seeing a turnaround in its financial performance, prompting a re-entry into investment portfolios.
After selling the stock last year due to deteriorating fundamentals, the author has observed improvements in earnings and margins, particularly in the second quarter where the company reported $112 billion in revenue and adjusted earnings of $6.38 per share. Management has also raised its full-year adjusted earnings guidance to between $19.50 and $20 per share.
Despite ongoing challenges with elevated medical costs, which have pressured insurance margins, the company's medical-care ratio improved to 86.7%, indicating better management of costs relative to premium revenue. The stock, currently priced at approximately $374, trades at about 18 times forward earnings and is about 20% below its 52-week high, presenting an attractive risk-reward scenario.
The author emphasizes the importance of patience in investing, highlighting that waiting for clear signs of improvement can lead to better investment decisions. UnitedHealth's consistent dividend growth, averaging 10% annually over the past five years, further supports its appeal as a recovery and income investment